Things
The HEAL ITALIA Program promotes a scheme based on cascade funding to support Proof-of-Concept (Po C) projects with industrial research and experimental development processes involving companies, specialized clinical centres, IRCCS, healthcare companies, organizations research institutions, Foundations, Consortium Companies, SMEs, start-ups, spin-offs and other entities interested in the creation/implementation of valorization and acceleration programs activated by the Spokes and managed in collaboration with the HUB. The objective is to increase the levels of technological maturity (TRL - Technology Readiness Levels) envisaged by the HEAL ITALIA Program, through the involvement of subjects external to the Extended Partnership, strongly interested in introducing/implementing significant innovations that act as a trailblazer and/or as tool for accelerating and specializing the activities carried out by the Spokes for the search for technologically advanced solutions, in relation to products, processes and services transferable to the areas of intervention of Precision Medicine.
Who is it aimed at?
Subjects external to the extended HEAL ITALIA partnership identified in: a) Public Administrations; b) Micro, Small and Medium Enterprises (MSMEs) which compete in single or collaborative mode with other companies, are eligible to submit project proposals in response to this Notice, having the dimensional parameters referred to in Annex I of REG (EC) n. 800/2008 of the Commission of 6 August 2008 (General block exemption regulation) in OJEU L 214 of 9.8.2008; c) Innovative startups established no more than 24 months ago (art. 25 of Legislative Decree 179/2012 - startup.registroimprese .it) of the National Health Service; g) Universities and bodies supervised by the MUR; h) Research Organizations registered in the National Research Registry (ANR);
What does it predict
The cascade call supports projects relating to activities that require a technological maturity level TRL higher than 3. Support therefore from the early research phases, mainly referring to the development/implementation of technologies with extremely advanced content, including conceptual verification and prototypes for the validation of the technology, demonstration activities for pilot projects and feasibility studies, also in order to be able to evaluate high potential activities and support the creation of spin-offs and start-ups. Summary of objectives SPOKE 8 – Clinical Exploitation: Clinical validation and implementation of innovative precision medicine approaches with predictive, preventive, diagnostic and therapeutic significance, based on clinical factors and emerging tools of phenotypic and/or genotypic molecular characterization and on decision-making protocols based on 'artificial intelligence. There are three themes covered by the announcement: TOPIC no. 1 Extended sequencing for the molecular characterization of tumor tissue samples and liquid biopsies and comparison with techniques routinely available in clinical practice. TOPIC no. 2 Development of additional omics profiling of cardio-metabolic disorders to identify risk mechanisms and devise clinical strategies aimed at molecular alterations of diseased cells. TOPIC no. 3 New strategies for clinical trial protocol development and coordination activities, including data management.
